Roth Capital reissued their buy rating on shares of TG Therapeutics Inc. (NASDAQ:TGTX) in a research report report published on Friday morning. Roth Capital currently has a $33.00 price objective on the biopharmaceutical company’s stock.

TGTX has been the subject of a number of other research reports. Brean Capital reiterated a buy rating and set a $28.00 target price on shares of TG Therapeutics in a research note on Thursday, October 6th. FBR & Co reissued a buy rating on shares of TG Therapeutics in a research report on Monday, September 19th. S&P Equity Research reduced their target price on shares of TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. Finally, Zacks Investment Research cut shares of TG Therapeutics from a strong-buy rating to a hold rating in a report on Thursday, July 14th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $21.21.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Shares of TG Therapeutics (NASDAQ:TGTX) traded down 2.88% during mid-day trading on Friday, reaching $6.40. The company’s stock had a trading volume of 149,046 shares. The stock’s market cap is $348.52 million. The stock has a 50 day moving average of $7.39 and a 200-day moving average of $7.37. TG Therapeutics has a one year low of $5.41 and a one year high of $14.87.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%. On average, equities research analysts expect that TG Therapeutics will post ($1.22) EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Advisors LLC increased its stake in TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 2,296 shares during the period. Vanguard Group Inc. increased its stake in TG Therapeutics by 11.5% in the second quarter. Vanguard Group Inc. now owns 1,484,133 shares of the biopharmaceutical company’s stock worth $8,995,000 after buying an additional 152,700 shares during the last quarter. SECOR Capital Advisors LP acquired a new stake in TG Therapeutics during the second quarter worth approximately $187,000. Nationwide Fund Advisors increased its stake in TG Therapeutics by 387.7% in the second quarter. Nationwide Fund Advisors now owns 108,904 shares of the biopharmaceutical company’s stock worth $660,000 after buying an additional 86,573 shares during the last quarter. Finally, Oxford Asset Management acquired a new stake in TG Therapeutics during the second quarter worth approximately $475,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.